Work

Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Year: 2020

Type: article

Study design: Clinical Trial

Source: International Journal of Hematology

DOI: 10.1007/s12185-020-03024-3

Authors: Koji Izutsu, Kazuhito Yamamoto, Koji Kato, Takayuki Ishikawa, Noriko Fukuhara, Yasuhito Terui, Ilseung Choi, Kathryn Humphrey, Su Young Kim, Sumiko Okubo, Natsumi Ogawa, Yasuko Nishimura, Ahmed Hamed Salem, Dai Maruyama

Institutions: Toranomon Hospital, National Cancer Center Hospital, Aichi Cancer Center, Kyushu University, Kyushu University Hospital, Kobe City Medical Center General Hospital, Tohoku University Hospital, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, National Hospital Organization Kyushu Cancer Center, F. Hoffmann-La Roche AG, AbbVie (United States), AbbVie (Japan)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: AbbVie, Genentech

OpenAlex ID: W3093819340

FWCI: 1.035

Cites: 37

Cited by: 20

Related to: 10